| Product sales and services | 31.34M |
| License and research revenue | 747K |
| Total | 32.09M |
| Cost of products and services sold | 2.84M |
| Research and development expenses | 8.14M |
| Selling, general and administrative expenses | 12.74M |
| Intangible asset amortization | 3.7M |
| Changes in fair value of related party acquisition-related contingent consideration | 20.85M |
| Total | 48.28M |
| Operating income (loss) | -16.19M |
| Investment Income | 490K |
| Interest Expense | -264K |
| Interest Expense - changes in fair value of financing-related contingent consideration | -1.83M |
| Foreign exchange gain (loss) | 1.25M |
| Income (loss) before income taxes | -16.54M |
| Income tax provision (benefit) | 3.45M |
| Net income (loss) | -19.99M |
| Continuing operations | |
| Discontinued operations | |
| Net income (loss) | -0.48 |
| Continuing operations | |
| Discontinued operations | |
| Net income (loss) | -0.48 |
| Weighted average number of shares outstanding - Basic (in shares) | 41.24M |
| Weighted average number of shares outstanding - Diluted (in shares) | 41.24M |